Activity of human β-defensins 2 and 3 against ESBL-producing Klebsiella strains
Open Access
- 25 January 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 57 (3) , 562-565
- https://doi.org/10.1093/jac/dkl003
Abstract
Objectives: To test the bactericidal activity of human β-defensins (hBDs) 2 and 3 against extended-spectrum β-lactamase (ESBL)-producing Klebsiella strains. Methods: Thirty-six Klebsiella pneumoniae and seventeen Klebsiella oxytoca ESBL-producing isolates from nosocomial infections were tested. The bactericidal activity of recombinantly synthesized hBD-2 and -3 was tested and the results were given either as lethal doses killing ≥90% of bacteria (LD90s) or as MBCs (≥99.9% killing). Results: Except for one intermediately susceptible strain (MBC = 25 mg/L), all other ESBL-producing strains were highly susceptible to both defensins (LD90s and MBCs ≤ 12.5mg/L). Conclusions: The results underline the high efficacy of hBD-2 and -3 against ESBL-producing Klebsiella, making both defensins attractive candidates as antimicrobial agents to combat these increasingly troublesome bacteria.Keywords
This publication has 12 references indexed in Scilit:
- Primate β-defensins - Structure, Function and EvolutionCurrent Protein & Peptide Science, 2005
- Increased Serum Resistance in Klebsiella pneumoniae Strains Producing Extended-Spectrum β-LactamasesAntimicrobial Agents and Chemotherapy, 2004
- Burkholderia Is Highly Resistant to Human Beta-Defensin 3Antimicrobial Agents and Chemotherapy, 2003
- Community-Acquired Klebsiella pneumoniae Bacteremia: Global Differences in Clinical PatternsEmerging Infectious Diseases, 2002
- Evolution and epidemiology of extended-spectrum β-lactamases (ESBLs) and ESBL-producing microorganismsClinical Microbiology & Infection, 2001
- Variations in the Prevalence of Strains Expressing an Extended‐Spectrum β‐Lactamase Phenotype and Characterization of Isolates from Europe, the Americas, and the Western Pacific RegionClinical Infectious Diseases, 2001
- Emergence of imipenem resistance in Klebsiella pneumoniae owing to combination of plasmid-mediated CMY-4 and permeability alterationJournal of Antimicrobial Chemotherapy, 2000
- Klebsiellaspp. as Nosocomial Pathogens: Epidemiology, Taxonomy, Typing Methods, and Pathogenicity FactorsClinical Microbiology Reviews, 1998
- Gram-negative bacteremia in non-neutropenic patients: A 3-year reviewInfection, 1998
- A peptide antibiotic from human skinNature, 1997